Still, our findings support associations of IL6 perturbation with ASCVD across all major vascular beds (coronary, cerebrovascular and peripheral), reinforcing the rationale for advancing IL-6-targeting therapies to clinical testing. This evidence concerns the gene IL6 and atherosclerosis.